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Abstract
Human cytomegalovirus (CMV) exerts diverse and complex effects on the immune system, not all of which have been
attributed to viral genes. Acute CMV infection results in transient restrictions in T cell proliferative ability, which can impair
the control of the virus and increase the risk of secondary infections in patients with weakened or immature immune
systems. In a search for new immunomodulatory proteins, we investigated the UL11 protein, a member of the CMV RL11
family. This protein family is defined by the RL11 domain, which has homology to immunoglobulin domains and adenoviral
immunomodulatory proteins. We show that pUL11 is expressed on the cell surface and induces intercellular interactions
with leukocytes. This was demonstrated to be due to the interaction of pUL11 with the receptor tyrosine phosphatase
CD45, identified by mass spectrometry analysis of pUL11-associated proteins. CD45 expression is sufficient to mediate the
interaction with pUL11 and is required for pUL11 binding to T cells, indicating that pUL11 is a specific CD45 ligand. CD45
has a pivotal function regulating T cell signaling thresholds; in its absence, the Src family kinase Lck is inactive and signaling
through the T cell receptor (TCR) is therefore shut off. In the presence of pUL11, several CD45-mediated functions were
inhibited. The induction of tyrosine phosphorylation of multiple signaling proteins upon TCR stimulation was reduced and T
cell proliferation was impaired. We therefore conclude that pUL11 has immunosuppressive properties, and that disruption
of T cell function via inhibition of CD45 is a previously unknown immunomodulatory strategy of CMV.
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Introduction
Infection of immunocompetent individuals with human cyto-
megalovirus(CMV) rarely results in symptomatic disease. Following
primary infection children and even adults often shed the virus in
saliva or urine for weeks or months [1], suggesting that clearance of
CMV by the immune system is a complex process. Cellular
immunity, in particular Natural Killer (NK) cells and CD8 T cells,
has been found to be pivotal in controlling CMV [2,3]. Yet, despite
the induction of strong cellular immune responses and neutralizing
antibodies, CMV is able to establish a latent infection, and
reactivation as well as reinfection with multiple CMV strains seems
to be quite frequent [4–6]. These properties of CMV have been
ascribed to the expression of a series of viral immunomodulatory
proteins [3,7]. In individuals with weakened or immature immune
systems the balance between host immune control and viral
immunomodulationcaneasilybeshiftedinfavorofviralreplication,
resulting in viremia and end-organ disease associated with
morbidity and even mortality in CMV-infected transplant recipi-
ents, AIDS patients or children congenitally infected with CMV[8].
It is a long standing observation that T lymphocytes in patients
with acute CMV infection display reduced proliferation capacity
[9–13] that may result in transient immunosuppression associated
with an increased risk of secondary infection [14,15]. A number of
mechanisms have been proposed by which CMV may interfere
with the priming of T cells as well as with their effector functions.
The inhibition of MHC class I antigen presentation pathways by
CMV is well established; limiting the recognition and lysis of
infected cells by cytolytic T lymphocytes [7,16]. Another strategy
that acts on the ability of T cells to proliferate is the secretion of
host and virally encoded suppressive factors from CMV-infected
cells; the virus induces enhanced secretion of transforming growth
factor b1 and soluble CD83, and itself encodes an interleukin-10
homologue that suppresses T cell proliferation [17–20]. Other
suppressive functions require direct contact between infected cells
and T cells [12]. An example is the upregulation of pro-apoptotic
ligands on the surface of CMV-infected dendritic cells that can
induce apoptosis in activated T cells [21]. The observation that the
fraction of T cells that is not driven into apoptosis is also unable to
proliferate normally after contact with CMV-infected cells implies
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possibility could be the interaction of CMV-encoded surface
proteins with regulatory or inhibitory receptors on T cells.
Cellular proteins and also immunomodulatory proteins of
various viruses that mediate the interaction with surface proteins
of immune cells often contain immunoglobulin-like or MHC-like
domains [22–24]. The CMV genome encodes a number of
putative transmembrane proteins with such a property [25], the
most prominent being the RL11 family that includes 14 largely
uncharacterized proteins. The defining motif of this family is the
RL11 domain, which has limited sequence homology to
immunoglobulin domains and to the immunomodulatory E3
proteins of adenoviruses [26]. The only member of the RL11
family that has been studied more thoroughly, the TRL11/IRL11
protein, encodes an Fc-receptor that binds human immunoglob-
ulins, presumably mediating escape from recognition by anti-viral
immunoglobulins [27,28]. In this study we focused on another
member of the RL11 family, the UL11 protein that has previously
been reported to be expressed on the cell surface of CMV-infected
cells [29] and therefore has the potential to interact with T cell
receptor molecules.
The restricted proliferative capacity of T cells from CMV-
infected patients has been linked with defects in T cell receptor
(TCR) signaling [30]. There are only a few transmembrane
proteins on T cells that may exert negative regulatory effects on
TCR signaling, the most prominent being the receptor tyrosine
phosphatase CD45. The CD45 protein is an essential regulator of
the TCR signaling pathway that determines the sensitivity of T
cells to TCR mediated stimulation. The absence of CD45 leads to
a severe combined immunodeficiency (SCID) phenotype in
humans [31–33] and mice [34–36]. The key substrate of the
CD45 phosphatase in TCR signaling is the Src family kinase Lck
[37], which is in close proximity to the TCR and, upon activation
by an incoming stimulatory signal, phosphorylates immunorecep-
tor tyrosine-based activation motifs (ITAMs) in subunits of the
CD3-TCR complex [38,39]. In common with other Src family
kinases, Lck is regulated via the phosphorylation status of one
inhibitory and one activating tyrosine residue; Y505 and Y394 in
Lck [40]. When phosphorylated, the negative regulatory tyrosine,
Y505, maintains an intramolecular interaction holding Lck in a
closed, inactive conformation [41–43]. CD45 dephosphorylates
Y505 and releases Lck into an open, primed form, ready to receive
a signal from the CD3-TCR complex that results in phosphor-
ylation of Y394 and thereby activates the kinase activity of Lck
[44–46]. CD45 also has a less favored inhibitory function, to
dephosphorylate Y394 [47–49]. For TCR signaling to occur, a
pool of primed Lck must be available. CD45 is the only
phosphatase known to dephosphorylate the inhibitory tyrosine of
Lck, and the action of CD45 is therefore essential in setting the
threshold at which incoming stimulating signals can be transduced
into effects [50].
In this study we show that the CMV UL11 protein interacts
with the CD45 receptor phosphatase on the surface of T cells,
inhibiting signaling and restricting T cell proliferation.
Results
The CMV UL11 ORF encodes a surface expressed
glycoprotein
The UL11 protein is predicted to be a type I transmembrane
protein (Figure 1A) and has previously been reported to be
expressed on the surface of human fibroblasts infected with the
highly passaged CMV laboratory strain AD169 [29]. Expression
of the protein from more physiologically relevant strains of the
virus and in other cell types has not been analyzed, but relatively
low levels of UL11 transcription from the Merlin strain of CMV
have been observed (Andrew Davison, personal communication).
To allow us to work with conveniently detectable levels of pUL11,
we therefore used an adenovirus expression system [51] and
constructed a recombinant adenovirus (rAdV UL11) expressing
pUL11 from the TB40/E strain of CMV [52] and GFP to allow
the identification of transduced cells. Using a polyclonal antiserum
specific for the predicted N-terminal extracellular domain of UL11
(Figure S1) we detected pUL11 on the surface of A549 lung
epithelial cells and human foreskin fibroblasts (HFF) transduced
with rAdV UL11, but not with a control adenovirus lacking UL11
(rAdV GFP) by flow cytometry (Figure 1B) and confocal
microscopy (Figure 1C). These results confirmed that pUL11 is
expressed at the cell surface and furthermore indicated that surface
expression of pUL11 does not require the presence of other CMV
proteins.
To characterize the UL11 protein, we transduced A549 cells
with rAdV UL11 and performed immunoblots of the cell lysates
using an antibody specific for the V5 epitope added at the C-
terminus of the UL11 protein. A prominent band of 50 kDa and
several faint bands with apparent molecular masses ranging from
60 to 72 kDa were detected (Figure 1D). This suggested
posttranslational modification of the UL11 protein since the
predicted molecular mass of pUL11 is 31 kDa. To investigate
potential glycosylation of pUL11, lysates of recombinant adeno-
virus transduced cells were treated with PNGase F, O-glycosidase,
or a combination of the two and immunoblotted (Figure 1E).
PNGase F treatment led to a reduction of the molecular mass of
pUL11 to approximately the predicted 31 kDa, but treatment with
O-glycosidase, either alone or in combination with PNGase F, had
no effect. N-linked glycosylation therefore appears to form all or
the majority of the post-translational modification of pUL11.
The extracellular domain of pUL11 interacts with a
200 kDa leukocyte cell surface protein
As pUL11 is expressed on the cell surface, its role could
potentially be to interact with proteins on the surface of
neighboring cells such as infiltrating immune effector cells in
Author Summary
The human cytomegalovirus (CMV) belongs to a class of
viruses that interferes with the immune response of its
host. Accordingly, infection with CMV is a severe risk for
immunologically immature newborns and immunocom-
promised patients such as transplant recipients. The
mechanisms by which CMV affects the immune system
are not completely understood. Here we show that a CMV
protein, pUL11, which is expressed on the surface of cells,
binds to leukocytes by interacting with the receptor
tyrosine phosphatase CD45. In T cells, CD45 is essential for
transmission of activating signals received via the T cell
receptor (TCR) to downstream effector molecules that
ultimately lead to activation and proliferation of these
immune cells. Binding of the CMV pUL11 protein to CD45
on T cells prevents signal transduction via the TCR and
restricts T cell proliferation. Interestingly, the mechanism
by which the activity of CD45 is regulated is a matter of
debate and no specific cellular ligand of CD45 has yet been
described. The identification of a first viral ligand for CD45
may provide the means to investigate CD45 regulatory
mechanisms and also allow the development of therapies
to interfere with CMV-mediated immunomodulation.
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extracellular domain with the Fc domain of human IgG fused at
the C-terminus (Figure S2) was used to measure interactions of
pUL11 with five different cell types by flow cytometry. Markedly
higher binding of UL11Fc than the control Fc domain (Fc) was
detected to the lymphocyte cell lines BJAB and Jurkat but not to
the non-hematopoietic cell lines HeLa, 293T or BJ fibroblasts
(Figure 2A). Extension of the study to primary PBMCs from a
healthy donor indicated interactions of UL11Fc with CD4 and
CD8 T cells, B cells, NK cells, monocytes and neutrophils
(Figure 2B). These data suggested that pUL11 binds to a protein
that is ubiquitously expressed on cells of hematopoietic origin.
To identify interaction partners of pUL11, proteins were
precipitated from Jurkat cell lysates using UL11Fc as bait. A
doublet of approximately 200 kDa and a few smaller proteins
precipitated from Jurkat cell lysates by UL11Fc were detectable by
Figure 1. pUL11 is a surface expressed glycoprotein. (A) Predicted structure of the UL11 protein. (B) Flow cytometry with a pUL11-specific
rabbit antiserum (black lines) or pre-immune serum (grey lines) of HFF or A549 cells transduced with recombinant adenoviruses expressing UL11 and
GFP (rAdV UL11) or GFP alone (rAdV GFP). Gating was on GFP positive cells. (C) Confocal microscopy of HFF and A549 cells transduced as in B) and
labeled at the cell surface with the anti-pUL11 serum and an Alexa-568 conjugated anti-rabbit antibody (shown in red). Size bar, 20 mm. (D)
Immunoblot with a mouse anti-V5 antibody of lysates of rAdV UL11, rAdV GFP or mock transduced A549 cells. (E) Lysates of rAdV UL11 transduced
A549 cells were treated with peptide N-glycosidase F (PNGase F), endo-a-N-acetylgalactosaminidase (O-glycosidase) or untreated as indicated.
Immunoblotting was performed as in (D). (D, E) Left margin, molecular mass (in kDa); right margin, the arrowhead and the bracket indicate low and
high molecular weight forms of pUL11.
doi:10.1371/journal.ppat.1002432.g001
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present when the Fc control protein was used as bait (Figure 3A,
lane 1) or when proteins were precipitated from 293T cells with
UL11Fc (Figure 3A, lane 4).
Since pUL11 interacts with a leukocyte surface protein, we
wished to determine which of the proteins precipitated from Jurkat
lysates were surface proteins. Jurkat or 293T cells were labeled with
membrane impermeable biotin before lysis and precipitation with
UL11Fc, the Fc domain alone, or as a positive control with an
antibody specific for the CD3 e-chain. Following blotting and
detection using peroxidase-coupled streptavidin (Figure 3B), the
200 kDa doublet produced the strongest signal of the proteins from
Jurkat lysates precipitated by UL11Fc (Figure 3B, lane 2), whereas
theseproteinswere not precipitated bytheFcdomain,orthe CD3-e
antibody (Figure 3B, lanes 1 and 6). As expected a 23 kDa protein
immunoprecipitated by the CD3-e antibody from Jurkat cell lysates
could be visualized (Figure 3B, lane 6). These data suggest that the
200 kDa proteins are on the surface of Jurkat cells.
Figure 2. pUL11 interacts with leukocytes. (A) Surface staining of the indicated cell lines with purified UL11Fc (black lines), or the Fc control
protein (grey lines). (B) Purified UL11Fc or Fc proteins were incubated with primary PBMCs. Surface markers and cell size were used to set gates for
different leukocyte subpopulations.
doi:10.1371/journal.ppat.1002432.g002
Figure 3. pUL11 interacts with a T cell surface protein with an approximate mass of 200 kDa. (A) Lysates of Jurkat or 293T cells, or lysis
buffer, were incubated with UL11Fc (UL11) or the Fc control protein (Fc) and protein A sepharose beads. The bound proteins were separated by SDS-
PAGE and detected by silver staining. (B) Jurkat or 293T cells were biotinylated prior to lysis. Proteins interacting with UL11Fc, the Fc domain or a
CD3e antibody were precipitated as in (A) and detected after blotting using HRP-streptavidin. A doublet at approx. 200 kDa is indicated.
doi:10.1371/journal.ppat.1002432.g003
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was subjected to mass spectrometric analysis. Eight peptides
stemming from the receptor tyrosine phosphatase CD45 were
detected, and no other peptides corresponding to surface proteins,
suggesting that CD45 is the interaction partner of pUL11.
The interaction partner of pUL11 is the receptor tyrosine
phosphatase CD45
To confirm the interaction of pUL11 with CD45, the proteins
precipitated from Jurkat cell lysates by UL11Fc were analyzed by
immunoblotting with an antibody against CD45 (Figure 4A).
CD45 was detectable in Jurkat, but not 293T cell lysates
(Figure 4A, upper panel, lanes 3 and 4), and corresponding
reactivity was observed with the 200 kDa protein doublet
precipitated from Jurkat lysates by UL11Fc but not the control
Fc domain (Figure 4A, upper panel, lanes 1 and 2). This confirms
that pUL11 can interact with CD45 from Jurkat cell lysates. As a
control for the specificity of the interaction, we also analyzed the
precipitated proteins by immunoblotting using an antibody against
CD43. CD43 has no homology to CD45, but a similarly sized and
glycosylated ectodomain to CD45RABC [53], and the lectin
MGL, which interacts with CD45, also binds to CD43 in Jurkat
cells [54]. CD43 could be detected in Jurkat lysates (Figure 4A,
lower panel, lane 4), but not in proteins precipitated by UL11Fc
(Figure 4A, lower panel, lane 1).
CD45 is expressed on the surface of all nucleated hematopoietic
cells [55] and could therefore be the interaction partner of pUL11
seen upon flow cytometric analysis of leukocytes (Figure 2B). To
test this assumption, we analyzed the interaction of pUL11 with T
cell lines that do not express CD45. The J-AS-1 cell line is a Jurkat
cell line in which CD45 expression has been selectively disrupted
by the stable expression of antisense RNA [56]. The J45.01 cell
line was independently derived from Jurkat cells by irradiation and
selection for loss of CD45 expression [57]. In both of these cell
lines, the lack of CD45 expression coincided with the lack of
UL11Fc binding (Figure 4B), indicating that CD45 expression is
needed for the interaction. To show that CD45 expression is
sufficient to induce the interaction of pUL11, we expressed the R0
and RABC isoforms of CD45 in 293T cells by transient
transfection. In both cases, an interaction of UL11Fc with the
cells expressing CD45 could be seen (Figure 4C). The amount of
UL11Fc that binds to the cell surface increases with higher surface
expression of CD45, indicating that the interaction is concentra-
tion dependent (Figure 4C, top row). Cells were also transiently
transfected with expression plasmids encoding other surface
glycoproteins; murine CD45 and human CD43. No interactions
of UL11Fc were detected with cells expressing these proteins
(Figure 4C, top and middle rows). Furthermore, binding of the
extracellular domain of another member of the RL11 family,
pUL6 (Figure S2), to 293T cells was not affected by transfection
with either of the CD45 isoforms (Figure 4C, bottom row). The
presence of CD45 on the cell surface therefore appears to be
sufficient to induce a specific interaction with pUL11 and no
detectable interactions occur between pUL11 and other T cell
surface proteins.
To confirm by another method that pUL11 binds to Jurkat cells
via CD45, we incubated Jurkat cells with antibodies directed
against CD45 and then analyzed subsequent UL11Fc binding by
flow cytometry. The AICD45.2 antibody that recognizes all
isoforms of CD45 [58] blocked UL11Fc binding in a concentra-
tion dependent manner (Figure 4D). A second pan-CD45
antibody, MEM-28, had a marginal effect, and the UCHL-1
antibody that recognizes only the CD45R0 isoform [59] had no
effect at all on UL11Fc binding (Figure S3). This experiment
therefore supports the conclusion that pUL11 binding is CD45
dependent.
The UL11 protein shows a high degree of polymorphism
between different strains of CMV [25,29] and so, in order to
determine whether the interaction with CD45 is restricted to
pUL11 from the TB40/E strain of CMV, or a more general
property of the protein, we investigated pUL11 from two
additional CMV strains; Toledo and AD169. The predicted
extracellular domains of the Toledo and AD169 UL11 proteins
were also expressed as Fc fusion proteins and the binding of all
three variants of UL11Fc to Jurkat and CD45 negative J-AS-1 cells
was compared (Figure 4E). All three forms of pUL11 interacted
with Jurkat but not with CD45-negative J-AS-1 cells, interestingly
with some apparent quantitative differences in binding. This
experiment indicated that the interaction of pUL11 with CD45 is
not strain-specific.
We were interested in whether the complete, surface expressed
UL11 protein also interacts with CD45. To investigate this
question, we transduced HFF cells with rAdV UL11 or the control
rAdV GFP adenovirus and incubated these presenter cells with
PBMCs, Jurkat or J-AS-1 cells lacking CD45. After washing away
the unbound cells, rosetting of PBMCs and Jurkat cells around the
pUL11 expressing cells could be clearly seen (Figure 5A, top two
rows), and was absent from the control cells. No rosetting of the J-
AS-1 cells was seen (Figure 5A, third row), indicating requirements
for both CD45 and pUL11 for the interaction to take place. The
binding of Jurkat cells to rAdV UL11 transduced fibroblasts could
be disrupted following treatment of the transduced cells with
UL11-specific antiserum, but not with pre-immune serum
(Figure 5B, middle and bottom rows). This indicates that the
adhesion properties of the soluble extracellular UL11Fc protein
are also representative of full-length transmembrane pUL11.
pUL11 interacts with CD45 on both naı ¨ve and activated T
cells
Five different isoforms of CD45, generated by variation in
splicing, have been detected in human lymphocytes. The
expression of these isoforms is tightly controlled, depending on
cell type, stimulation and maturation [60]. Naı ¨ve T cells typically
express high molecular weight isoforms of CD45 containing exon
A encoded domains. The RA isoforms are downregulated during
activation. The expression of the R0 isoform, due to removal of
exons A, B and C by splicing, is the major CD45 protein species
characteristic for primed and memory T cells [61]. In individuals
with a variant form of the CD45 gene, typified by the C77G
polymorphism, the splicing pattern of CD45 is altered, meaning
that T cells expressing both long RA and short R0 isoforms of
CD45 are present after activation [62,63]. In addition to CD45
splicing, the glycosylation of the different isoforms is also affected
by cell stimulation, which could potentially affect the interaction
with pUL11 [60]. It was of interest to understand whether pUL11
interacts preferentially with forms of CD45 associated with a
particular activation state of T cells. Primary T cells from both
control (C77C) and variant (C77G) individuals were therefore
stained with antibodies against RA and R0 isoforms of CD45 and
co-incubated with UL11Fc (Figure 6A). Binding of UL11Fc could
be seen to cells expressing either RA, or R0 or both types of CD45
isoforms. Upon stimulation of the cells with phytohaemagglutinin
and interleukin-2, the CD45 isoform expression pattern changed,
but UL11Fc binding to all cell populations was unaltered
(Figure 6B). This indicates that pUL11 can interact with both
long and short isoforms of CD45 on both naı ¨ve and mature T
cells.
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CD45 in T cells functions to prime the tyrosine kinase Lck,
enabling TCR dependent signaling leading to activation and
proliferation. Stimulation through the TCR-CD3 complex
activates a signaling cascade resulting in the increased tyrosine
phosphorylation of multiple downstream signaling intermediates
[64]. To investigate the effect of pUL11 on this function of CD45,
we stimulated Jurkat T cells with the C305 anti-Jurkat TCR
antibody in the presence and absence of UL11Fc and detected
induced changes in tyrosine phosphorylation by immunoblotting.
In untreated cells and cells preincubated with the Fc control
protein, the expected increase in tyrosine phosphorylation was
readily detectable upon TCR stimulation (Figure 7A, left and right
panels). In cells preincubated with UL11Fc, however, this increase
was strongly reduced (Figure 7A, middle panel), indicating an
inhibitory effect of pUL11 on T cell signaling.
Activation of T cells through TCR signaling leads to their
proliferation. To determine whether T cell proliferation is also
disrupted by pUL11 treatment, we measured the effects of
UL11Fc on the proliferation of primary T cells in response to
stimulation via CD3 (Figure 7B). T cells were incubated with the
OKT3 CD3 antibody or with the mitogen phytohaemagglutinin,
in the presence of UL11Fc or the Fc control protein. After 72 h,
proliferation was measured and an inhibitory effect of UL11Fc
could be seen. pUL11 therefore affects T cell functions that
require active CD45, resulting in reduced TCR signaling and
proliferation.
Discussion
Immune suppression induced by acute CMV infection can have
serious consequences for patients with impaired immune func-
tions, such as an increased incidence of severe secondary bacterial
and fungal infections in solid organ transplant recipients [65]. As a
starting point to identify new CMV encoded immunosuppressive
proteins, we considered the RL11 gene family. The RL11 proteins
are largely uncharacterized, but the majority possesses the RL11
domain, a variable region of between 65 and 82 residues that has
some sequence homology to the adenovirus CR1 domain and to
immunoglobulin domains [26]. Adenovirus proteins containing
the CR1 domain include immunomodulatory E3 proteins [26,66],
and immunoglobulin domains are commonly required for both
cellular and viral protein interactions with cell surface components
of the immune system [22,23].
Acute CMV infection results in a reduction in the proliferation
capacity of lymphocytes, which are not themselves infected by the
virus [11]. A similar effect is produced in vitro upon contact
between lymphocytes and CMV-infected cells, indicating the
potential existence of uncharacterized surface expressed viral
proteins with immunomodulatory properties [12,21]. As it has
previously been proposed that the RL11 domain containing
protein pUL11 is expressed on the surface of human fibroblasts
infected with the AD169 laboratory strain of CMV [29], we
considered pUL11 to be a good candidate for a novel
immunosuppressive protein. The surface staining of CMV-
infected cells with a UL11-specific rabbit serum was interpreted
by Hitomi et al. [29] as proof of the surface expression of UL11,
however, it might rather have reflected the binding of rabbit
immunoglobulins to the virally encoded Fc-receptors, as has
previously reported by other authors [67,68]. Despite the
published description of pUL11 surface expression [29], we could
only observe low levels of UL11 mRNAs in fibroblasts or epithelial
cells infected with the AD169 or TB40/E strains of CMV (data
not shown), in agreement with data using the Merlin strain of
CMV (Andrew Davison, personal communication). Therefore, we
first re-evaluated whether the UL11 protein from the TB40/E
strain of CMV can be expressed on the surface of fibroblasts and
epithelial cells, using a recombinant adenovirus expression system.
The surface expression of pUL11 that we detected then led us to
search for interactions between pUL11 and surface molecules on
different cell types. The predicted extracellular domain of pUL11
was used in flow cytometry binding studies and interacted with
leukocyte cell lines and primary leukocytes, but not with control
cell lines of non-hematopoietic origin, indicating an interaction
with a leukocyte specific receptor. Mass spectrometry analysis of
surface proteins pulled down by the pUL11 extracellular domain
from Jurkat cell lysates identified the receptor tyrosine phosphatase
CD45 as a binding partner of pUL11. That CD45 is also
responsible for the interaction of pUL11 with leukocytes seen in
flow cytometry analysis was confirmed using two different CD45
deficient cell lines. No interactions could be seen between pUL11
and the Jurkat derived CD45 negative cell lines J-AS-1 or J45.01
[56,57]. The interaction of pUL11 with the surface of leukocytes
could also be demonstrated using fibroblasts expressing full-length
pUL11, to which PBMCs and CD45 expressing T cells adhered.
The interaction of pUL11 with Jurkat cells could be blocked by
pretreatment with either an CD45 antibody, or pUL11 antiserum,
confirming the specificity of the interaction. As pUL11 shows
sequence variation between different strains of CMV [25,29], we
purified the predicted extracellular domain of pUL11 from two
additional CMV strains, Toledo and AD169, and showed that
these forms of pUL11 also interact specifically with CD45
expressing cell lines, apparently with some differences in affinities,
demonstrating that the interaction is not a peculiarity of the
TB40/E form of pUL11. Expression of two different isoforms of
CD45 in 293T cells both induced pUL11 binding, indicating that
CD45 is sufficient for the interaction. A second member of the
RL11 family, pUL6, was used to investigate whether the
interaction with CD45 is a general property of RL11 proteins,
or specific to pUL11. No changes in pUL6 binding were seen in
relation to CD45 expression, indicating that the interaction is a
Figure 4. pUL11 interacts with CD45. (A) Immunoblot with anti-CD45 (upper panel) or anti-CD43 (lower panel) of lysates from 293T and Jurkat (J)
cells and proteins precipitated from Jurkat cell lysates with UL11Fc or Fc control protein. Bands corresponding to CD45 and CD43 proteins in Jurkat
lysates are indicated. (B) Flow cytometric analysis of the interactions of UL11Fc (black lines, top panel), Fc control protein (grey lines, top panel), CD45
antibody (black lines, middle panel) and UL6Fc (black lines, bottom panel) with Jurkat cells or the Jurkat derived cell lines J-AS-1 and J45.01. Grey lines
in middle panels, staining with an isotype-matched control antibody. (C) Binding of UL11Fc (top row, density plots and second row, black lines), Fc
control (grey lines) or UL6Fc (third row, black lines) to 293T cells that were mock transfected or transiently transfected with plasmids encoding either
human CD45RABC or CD45R0 isoforms, mouse CD45RB or human CD43. Expression of hCD45, mCD45 and hCD43 is shown in density plots in upper
panels with rectangles indicating gates for cells analyzed for UL11Fc and UL6Fc binding (rows 2 and 3). 48 h post transfection, cells were incubated
with the indicated Fc proteins and co-stained with PE-labeled anti-IgG and FITC-labeled anti-human CD45 or anti-mouse CD45 or anti-human CD43
antibodies. (D) Inhibition of binding of UL11Fc to Jurkat cells by the AICD45.2 CD45 antibody. Cells were incubated with the indicated amounts of
AICD45.2 for 30 min, prior to incubation with UL11Fc (black lines) or Fc control protein (grey lines). (E) Interactions of UL11Fc derived from TB40E,
Toledo or AD169 strains of CMV (black lines, 3 leftmost columns), or Fc control protein (grey lines, 3 leftmost columns) with Jurkat (top row) or J-AS-1
cells (bottom row). Staining with anti-CD45 (black lines) or an isotype-matched control antibody (grey lines) is shown in the right hand column.
doi:10.1371/journal.ppat.1002432.g004
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not be induced by expression of the mouse CD45 protein, or the
human CD43 glycoprotein in 293T cells. In conjunction with the
observation that pUL11 binding is abrogated in the CD45
deficient T cell lines, this provides strong evidence that pUL11
interacts with CD45 and that the interaction is specific.
CD45 exists as a set of different isoforms, the expression and
glycosylation of which is tightly controlled and depends on cell
type and maturation state. We demonstrated that the interaction
of pUL11 with primary T cells is not dependent upon T cell
activation state, as interactions were detectable between pUL11
and both long and short isoforms of CD45, expressed on both
naı ¨ve and mature T cells. This implies that the immunomodula-
tory effects of pUL11 in vivo may be wide ranging, potentially
affecting both priming and effector functions of T cells.
The interaction of pUL11 with CD45 is markedly different from
that of other known CD45 ligands. The other CD45 ligands that
have been described are all lectins, which recognize oligosaccha-
ride moieties with specificities determined by the lectin carbohy-
drate recognition domains [69]. Lectins typically bind to multiple
ligands and have pronounced differences in their interactions with
the various CD45 isoforms and glycoforms due to their differing
glycosylation patterns [60]. The C-type lectin macrophage
galactose type lectin (MGL), a pattern recognition receptor on
myeloid antigen presenting cells which recognizes N-acetylgalac-
tosamine (GalNAc) sugars, for example, binds only to the longer
isoforms of CD45 due to their higher GalNAc content, and also to
the sialoglycoprotein CD43 [54]. Other lectins are even more
specific in their preferences; glucosidase II and serum-mannan
binding protein only interact with CD45 glycoforms characteris-
tically found on immature thymocytes; in the case of serum-
mannan binding protein only with the hybrid-type N-linked
glycans on the R0 isoform [70,71]. Lectin ligands for CD45
frequently do not show reduced surface binding to CD45 negative
T cell lines, due to the abundance of other suitably glycosylated
ligands [54,72], and in contrast to the binding pattern observed for
pUL11. As pUL11 interacts with diverse forms of CD45 and
shows no detectable binding to CD45 negative T cells, its
interaction with CD45 seems to be of a different nature from
those of previously described ligands.
CD45 is necessary for T cell functions mediated via signaling
through the TCR complex. The Src family kinase Lck is primed
by CD45-mediated dephosphorylation of tyrosine 505, which
releases an intramolecular bond holding Lck in a closed, inactive
conformation [50]. In the absence of primed Lck, signal
transduction through the TCR cannot be initiated [73] and
inhibition of TCR mediated signaling functions is therefore
characteristic of reduced CD45 function [74]. Pretreatment with
pUL11 reduced the cascade of tyrosine phosphorylation triggered
by T cell stimulation with an anti-TCR antibody and TCR
dependent T cell proliferation was also inhibited. These effects
indicate that signal transduction through the TCR is impaired in
the presence of pUL11, and are consistent with a restriction in
CD45 function.
Figure 5. Surface expressed pUL11 mediates cell adhesion. (A) PBMCs, Jurkat or J-AS-1 cells were incubated with human fibroblasts that were
transduced 3 days earlier with recombinant adenoviruses expressing pUL11 and GFP (rAdV UL11) or GFP alone (rAdV GFP). Unbound cells were
removed by washing. White arrows indicate adhering cells, green cells show adenovirus derived GFP. Size bar, 50 mm. (B) Human fibroblasts
transduced and depicted as in (A) were left untreated (top row), or incubated for 2 h with anti-UL11 (middle row) or pre-immune rabbit serum
(bottom row) prior to incubation with Jurkat cells. Unbound cells were removed by washing. Size bar, 50 mm.
doi:10.1371/journal.ppat.1002432.g005
Figure 6. pUL11 interacts with T cells expressing both long and short isoforms of CD45. Primary T cells from donors with control or
variant CD45 isoform expression were either left untreated (A) or stimulated with phytohaemagglutinin and interleukin-2 (B), and subsequently
incubated with UL11Fc (black lines) or the Fc control protein (grey lines) and co-stained with anti-CD45RA or anti-CD45R0 antibodies. Interaction of
the Fc proteins is depicted for cells gated as R0 positive, RA positive, or R0 and RA double positive as indicated.
doi:10.1371/journal.ppat.1002432.g006
HCMV UL11 Inhibits CD45 Mediated T Cell Functions
PLoS Pathogens | www.plospathogens.org 9 December 2011 | Volume 7 | Issue 12 | e1002432The critical control of signaling thresholds by CD45 implies that
its effects must be tightly regulated. Although this process is not yet
fully understood, mechanisms have been proposed, some of which
are influenced by interactions of ligands with the extracellular
domain of CD45, and might therefore be applicable to pUL11
function. For CD45 to function correctly, it must have a tightly
controlled localization in the plasma membrane, with regulated
contact to substrate proteins. Lck is present in lipid rafts [75], and
a fraction of CD45 must have access to Lck to be able to
dephosphorylate residue Y505 and generate a pool of primed Lck.
This partial localization of CD45 in lipid rafts is dependent on the
extracellular domain of CD45 and may require interactions in cis
with other raft components [53,76]. As CD45 is a potent
phosphatase, it is however important that only a fraction is
present in lipid rafts. Excessive contact between CD45 and the
TCR signaling complex can result in dephosphorylation of the
active site tyrosine 394 of Lck and potentially of Lck substrates
such as ZAP-70 and the f-chain of the CD3-TCR complex,
blocking the initiation of signal transduction [48,77,78]. CD45 is
therefore excluded from the signaling complex by lipid raft
movements [76,79]. The inhibitory effects on CD45 function of
the therapeutic anti-CD45RB mAb 6G3 [80], and also the lectin
Figure 7. pUL11 treatment results in reduced T cell signaling and proliferation. (A) Immunoblot with the 4G10 phosphotyrosine-specific
antibody (upper panel) or anti-actin (lower panel) of lysates from Jurkat cells that were either left untreated or were pretreated with UL11Fc or the Fc
domain (2.5 mg) for 30 min prior to stimulation with a Jurkat TCR-specific antibody (C305) for the indicated times. (B) Primary T cells were either left
untreated (medium) or were incubated with the CD3-specific antibody OKT3 or with phytohaemagglutinin (PHA) together with BSA, UL11Fc or the Fc
domain (2 mg) for 3 days. Following incubation for 16 h with
3[H]-thymidine radionucleotide incorporation was measured. All samples were handled
in triplicate. Representative data from one of three experiments are shown.
doi:10.1371/journal.ppat.1002432.g007
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CD45 into lipid rafts, allowing a deactivation of Lck. It is
conceivable that an interaction with pUL11 could disrupt cis
interactions of the extracellular domain of CD45 with lipid raft
components, affecting the controlled partitioning of CD45 into
lipid rafts and thus generating the observed effects on T cell signal
transduction.
CD45 activity has also been described to be dependent on
dimerisation state; a model has been proposed in which
dimerisation results in the formation of an inhibitory structural
‘‘wedge’’ disrupting substrate access to the phosphatase domain
[82,83]. Reduced dimerisation associated with a prevalence of
high molecular weight forms of CD45 has been suggested to
underlie excessive CD45 activity resulting in hyperresponsive T
cell function [84,85]. Increased dimerisation, as seen by forced
dimerisation of a EGFR-CD45 hybrid molecule and the
interaction of the lectins galectin-1 and placental protein 14 with
CD45 decreases CD45 function [81,86,87]. An analogous role for
pUL11 is possible, in which pUL11 binding to the extracellular
domain of CD45 increases dimerisation, decreasing CD45
phosphatase activity and therefore restricting TCR signaling.
Other mechanistic interpretations, such as allosteric regulation
of CD45 phosphatase function upon ligand binding, potentially in
conjunction with those suggested here, are of course also possible.
Further investigations into the mechanisms of pUL11 function
seem likely to lead to new insights into CD45 regulation.
The role of pUL11 in the context of CMV infection is
intriguing; a transient general suppression of T cell function during
viral infection has been demonstrated [9–13] and the interaction
of pUL11 with CD45 may contribute to this effect. It is also clear
that a means for the virus to escape from CMV-specific T cell
control could enhance viral replication. The consequences of the
interaction with CD45 may also extend beyond effects on T cell
function as it is well known that CD45 plays important roles in
other classes of leukocytes [50]. The observation that UL11
proteins from three different strains of CMV all bind to CD45, but
apparently with some variation in affinity, is also interesting, as it
may point towards strain or host dependent immunosuppressive
effects of CMV infection. Before these questions can be addressed,
however, the expression profile of pUL11 during CMV infection
needs to be understood. We would speculate that the expression of
pUL11 may be cell type or state specific, but this remains to be
demonstrated.
In conclusion, we have identified CMV pUL11 as a novel,
specific interaction partner of CD45. pUL11 limits T cell signaling
and proliferation, effects which are consistent with a reduction in
CD45 activity. The interaction of pUL11 with CD45 appears to
represent a previously unknown pathway by which CMV can
induce immunosuppression, with potential therapeutic signifi-
cance.
Materials and Methods
Ethics statement
Human blood cells were provided by voluntary blood donors in
the Institute of Transfusion Medicine, Hannover Medical School.
All materials and data were analyzed anonymously. The use of the
human blood cells was approved by the ethics committee of
Hannover Medical School.
Cells
Human lung adenocarcinoma epithelial A549 cells and human
foreskin fibroblasts (HFF) were propagated in DMEM containing
10% FCS, 2 mM glutamine and 1% non-essential amino acids.
293T and 293A cells were maintained in DMEM containing 10%
FCS. Jurkat T cells, J45.01 cells [57] and J-AS-1 cells [56], were
cultured in RPMI 1640 with 2 mM glutamine and 10% FCS, with
the medium for the latter two cell lines supplemented with 20 mM
HEPES and for the J-AS-1 cells, also with G418 (0.5 mg/ml). For
protein production, retinal pigment epithelium (RPE) or 293T
cells were maintained in serum free Pro293a-CDM (LONZA),
containing 2 mM glutamine. PBMCs were flushed from leukocyte
filters used to prepare erythrocytes from healthy voluntary blood
donors for transfusion. Where indicated, the individuals were
identified as carrying wild type or C77G variant CD45. PBMCs
were isolated by density gradient centrifugation using Biocoll
Separating Solution or Ficoll (both from Biochrom) and
cryopreserved until usage. PBMCs were maintained in RPMI
1640 containing 20 mM HEPES or 1 mM sodium pyruvate,
4 mM glutamine and 10% FCS.
Recombinant adenoviruses
The recombinant adenoviruses rAdV UL11, rAdV GFP and
rAdV UL6Fc are based on the pAdZ-CV5 replication deficient
adenovirus vector [51]. First, the sequence for the V5 epitope tag
(GKPIPNPLLGLDST) was added at the 39-end of the UL11 open
reading frame (ORF) in the CMV TB40/E genome [52] by
homologous recombination in E. coli as previously described [88].
The UL11V5 fragment was amplified using the primers 59-AGT-
CGG-ATC-CAA-TTACCTGTGGTAGAATGC-39 and 59-GG-
C-CGG-ATC-CTT-ACG-TAG-AAT-CAA-GAC-C-TA-39 and
cloned into the pIRES eGFP vector (BD Biosciences Clontech).
The UL11V5 IRES eGFP cassette was then introduced into the
AdZ-CV5 vector by homologous recombination in the E.coli
SW102 strain as previously described [51]. rAdV GFP, rAdV
UL6Fc, rAdV Toledo UL11Fc and rAdV AD169 UL11Fc were
constructed by introducing the ORFs for GFP, Toledo UL11Fc,
AD169 UL11Fc and for UL6Fc (see below) into the pAdZ-CV5
vector. The correct construction of the adenovirus genomes was
confirmed by restriction analysis and sequencing. Recombinant
adenoviruses were produced and titered in 293A cells.
Fc fusion protein and antiserum production
The sequence encoding the predicted extracellular domain of
pUL11 was amplified from the genome of the CMV strain TB40/
E [52] using the primers 59-CGGGATCCATCA-GCC-T-C-C-
ACGATGCCTG-39 and 59-CCGGTCGACTGTAGCCACG-
TGTTGGTGC-39 and cloned into a pCR3-based vector con-
taining sequences encoding the mouse IgH signal peptide and
the Fc region of human IgG1 [89]. The predicted extracellular
domains of pUL11 from CMV strains Toledo and AD169 were
amplified from the respective viral genomes [90,91] using the
following primers and cloned into the same vector. pUL11
Toledo: 59-CGGGATCCATCAGCCTCCATGATGCCTG-39
and 59-CCGGTCGACTGT-GGC-CAC-G-T-G-TTGGTGC-39.
pUL11 AD169: 59-CGGGATCC-A-TCA-GTTTCCACGACCA-
TGC-39 and 59-CCGGTCGACTGTCGCCACGTGTTGGTA-
C-39. The sequence encoding the predicted extracellular domain of
pUL6 was amplified with the following primers: 59-CGG-GAT-
CCC-A-T-G-CTAAGATAAACGGGTGG-39 and 59-CCG-GTC-
GAC-GAA-TGC-CAA-GTTA-GTTA-TGT-T-C-39 and cloned
in an analogous manner. The ORF for the TB40/E UL11Fc
protein was amplified with the primers 59-CGG-CGG-CCG-CGC-
CAC-CAT-GAA-CTTCGGGTTC-39and59-CGGAATTCTCA-
TTTACCCGGAGACAGGG-39 and cloned into the pSFbeta91-
wpre replication deficient retrovirus vector [92]. The ORF for the
Fc domain of human IgG1 was cloned into the pSFbeta91-wpre
vector in a similar manner. Retroviruses were generated by
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wpre constructs together with the retroviral gag/pol plasmid M25-
DAW [93] and the feline endogenous retrovirus envelope
glycoprotein expression plasmid RD114 [94] and used to transduce
293T cells as described [92]. TB40/E UL11Fc, Toledo UL11Fc,
AD169 UL11Fc,UL6Fc and Fc control proteins were purified from
serum free supernatants of retrovirally transduced 293T cells or
adenovirally transduced RPE cells by protein A affinity chroma-
tography using hiTrap rProtein A FF columns (GE Healthcare,
Munich, Germany). The TB40/E UL11Fc protein was used to
generate a rabbit antiserum directed against the extracellular
domain of pUL11 (Pineda Antikoerper Service, Berlin, Germany).
Plasmid construction and transfection
Plasmids LCA.1 and LCA.6 that express the human CD45R0
and CD45RABC isoforms under control of the SR-alpha
promoter [56] were kindly provided by David Rothstein. The
CD45R0 ORF was removed from LCA.1 by treatment with Eco
RI and Sal I and replaced by an Mfe I/Sal I treated PCR fragment
encoding the transmembrane region and cytoplasmic tail of mouse
CD45, which was amplified with primers 59-GGCCAATT-
GACGCGT-GCGGCC-G-C-T-A-T-A-TT-C-C-T-G-GTGTTT-
CTGA-39 and 59-GGCCAATT-GCCCG-TCG-A-CCG-T-T-A-
TGAA-C-T-C-T-GGGTT-G-G-A-GCTG-39, using a plasmid
carrying the mouse CD45RB cDNA [95]. The resulting plasmid
was cut with Not I and a PCR fragment was added encoding the
extracellular domain of mouse CD45RB, which was amplified
from the mouse CD45RB cDNA using primers 59-GGCG-
CGGCCGC-ACG-CGT-A-G--G--G-GCACAGCTGAT-C-T-C--
C-A-G--AT-39 and 59-GGCGCGGCCGCTTT-AGCATTA-
AAA-T-T-T--GTTGACTCATTTC-39, leading to the mCD45
expression vector. A PCR fragment encoding the extracellular
domain of human CD43 was generated with primers 59-CC-
C-GCG-G-CC-GCTGTT-TCTTAG-GGACA-C-G--GC-39 and
59-GAG-GCG-GCC-GCG-CCT-CGT-GAG-TTC-T-C-A-TCT-
GGGTTCC-39 from a cDNA vector encoding human CD43
(Open Biosystems), and was cloned in an analogous manner,
resulting in the CD43 expression vector.
1610
6 HEK293T cells were transfected with 4 mgo ft h e
expression constructs using the Lipofectamine 2000 reagent, and
flow cytometric analysis as described below was performed 48 h
later. Detection of protein expression from the transfected cells was
using FITC-coupled MEM-28 anti-human CD45 (Immunotools),
FITC-coupled MEM-59 anti-human CD43 antibody (Immuno-
tools)orFITC-coupledIBL-5/25 anti-mouse CD45 (Immunotools).
Flow cytometry and microscopy
Cell surface expression of pUL11 was measured in HFF or
A549 cells, 72 h after transduction with the rAdV at a multiplicity
of infection (MOI) of 500 and 300, respectively. The pUL11-
specific antiserum was adsorbed for 8 h on uninfected A549 or
HFF cells before use. Cells were incubated with antiserum in
blocking solution (1% BSA, 0.1% gelatine, 2 mM EDTA in PBS)
followed by PE-conjugated goat anti-rabbit antibody (Open
Biosystems) in blocking solution containing 6% goat serum. All
steps were performed at 4uC. For flow cytometry based binding
assays, 2.5 mg of purified Fc fusion proteins were incubated with
1610
6 cells in blocking solution (5% mouse serum, 2 mM EDTA
in PBS). Bound Fc proteins were detected using PE-conjugated
anti-human IgG (Acris). To determine the effects of CD45
antibodies on Fc protein binding, cells were incubated with
MEM-28 (Immunotools), UCHL-1 [59] (kindly provided by P.
Beverley, University of Oxford, UK) or AICD45.2 [58] (kindly
provided by B. Schraven, University of Magdeburg, Germany)
antibodies in blocking solution for 30 min prior to incubation with
UL11Fc fusion protein. Sub-populations of PBMCs were identi-
fied using antibodies directed to the following surface markers; T
cells: anti-CD3-FITC (Immunotools), anti-CD4-Dy647 (Acris),
anti-CD8-PE-Dy590 (Antibodies-online). B cells: anti-CD19-PE-
Dy590 (Antibodies-online). NK cells: anti-CD56-APC (Immuno-
tools); NK cells were identified as CD56 positive and CD3
negative cells, monocytes: anti-CD14-APC (Immunotools) and
neutrophils: anti-CD15-FITC (BD). Measurements were per-
formed on a Beckmann Coulter Cytomics FC500 cytometer and
analyzed using CXP analysis software. FACS based binding assays
to stimulated CD4 T cells were performed using CD4 T cells
prepared from PBMCs from control or variant (CD45 C77G)
donors by positive MACS separation (Miltenyi Biotec) using the
OKT-4 anti-CD4 mAb purified from hybridoma. The purity of
the CD4 positive fraction was determined by FACS. Cells were
stained and measured immediately or were stimulated with 1 mg/
ml PHA (Murex Diagnostics Ltd.) for 24 h and then treated for 8
days with 25 U/ml IL-2 (Roche). For staining, the cells were
incubated in 50% mouse serum in PBS, followed by Fc fusion
protein (1 mg) for 45 min. After washing, cells were incubated with
FITC-conjugated anti-CD45RA and APC-conjugated anti-
CD45R0 antibodies (BD). Bound Fc fusion proteins were detected
using PE-conjugated anti-human IgG (Acris). Measurement was
performed using a FACSCalibur cytometer and analysis was
performed using WinMDI software, version 2.9. For confocal
microscopy A549 or HFF cells infected with rAdVs as described
above were incubated with the anti-pUL11 serum in blocking
solution (1% BSA, 0.1% gelatine, PBS), followed by Alexa 568
conjugated goat anti-rabbit (Invitrogen). Cells were fixed with 3%
paraformaldehyde and observed using a Zeiss LSM 510 Meta
Confocal Microscope. To observe leukocyte rosetting, HFF
infected 96 h earlier with rAdVs at an MOI of 500 were co-
cultured with Jurkat T cells, J-AS-1 T cells or freshly isolated
PBMCs at a ratio of 1:20 for 2 h at 37uC, and washed 8 times with
PBS. To determine the effects of antisera on leukocyte rosetting,
HFF cells infected with rAdVs as described were incubated for 2 h
at 37uC with 400 ml of the rabbit anti-UL11 serum or preimmune
serum diluted with 600 ml of DMEM. The serum was then
removed and the HFF co-cultured with E6.1 Jurkat T cells (2610
6
Jurkat cells per 1610
5 HFF) for another 2.5 h, followed by 15
washing steps with PBS. Images were taken using a Zeiss Axio
Observer light/epifluorescence microscope.
Protein analysis
Glycosylation was investigated using purified Fc proteins or
proteins of lysates from A549 cells transduced with rAdV at an
MOI of 100 72 h earlier and prepared using NP40 lysis buffer
(150 mM NaCl, 1% NP40, 10 mM Tris-HCl pH 7.4, 1 mM
EDTA, protease inhibitor cocktail [Calbiochem]). Cell lysates or
purified proteins were boiled for 5 min in denaturing buffer (0.5%
SDS, 0.5% 2-mercaptoethanol) before being treated with N-
glycosidase F (4 U) (Roche) or Endo-a-N-acetylgalactosaminidase
(2,000 U) and neuraminidase (100 U) (New England Biolabs) in
500 mM sodium phosphate buffer pH 7.6 containing 1% NP40
for 2 h or overnight at 37uC. Cell surface proteins were
biotinylated by incubating 2.5610
7cells/ml in PBS with 2 mM
Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific), for 30 min. The
cells were washed three times with 100 mM glycine in PBS and
then lysed in NP-40 lysis buffer. Proteins were pulled down or
immunoprecipitated from cell lysates prepared from 1610
8 cells/
ml of NP40 lysis buffer. 500 ml of cell lysate precleared by
incubation for 20 min with protein A sepharose CL-4B (GE
Healthcare) was incubated with 10 mg of Fc protein or antibody
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immunoprecipitated using OKT3 (eBioscience). The preparative
pull-down for mass spectrometric analysis used 2610
8 cells lysed in
1 ml of NP40 lysis buffer, incubated with 20 mg of protein and 20 ml
of protein A sepharose CL-4B. For silver staining of proteins, SDS-
PAGE gels were washed twice in 50% methanol/10% acetic acid
for 15 min each, once in 10% ethanol/5% acetic acid for 6 min,
and rinsed twice for 9 min in water. Gels were then incubated in
sodium hydrosulfite (20 ng/ml) for 9 min, followed by 0.1% silver
nitrate solution, containing 0.75 ml/ml 37% formaldehyde for a
further 9 min. Gels were then rinsed for 30 s in water and
transferred to a 3% sodium carbonate solution containing 0.1% of
37% formaldehyde and 10 ng/ml sodium thiosulfate. Development
was halted using stop solution (2.5% acetic acid, 5% Tris). For
detection of pUL11, CD45, CD43 and phosphotyrosine proteins by
immunoblotting a mouse anti-V5 antibody (Invitrogen), the rabbit
anti-pUL11 serum, the MEM-28 CD45 antibody (Immunotools),
the MEM-59 CD43 antibody (Immunotools) and the 4G10
phosphotyrosine antibody (Millipore) were used, respectively,
followed by incubation with the appropriate HRP-conjugated
anti-mouse or anti-rabbit antibodies (Dako).
T cell assays
Induction of tyrosine phosphorylation was measured after the
incubation of Fc fusion proteins (2.5 mg) with 4610
5 Jurkat cells in
100 ml of culture medium for 30 minutes at 37uC, followed by
stimulation with 100 ml of C305 anti-Jurkat TCR mAb [96]
hybridoma supernatant (kindly provided by B. Schraven, Univer-
sity of Magdeburg, Germany). Stimulation was stopped by the
addition of 1 ml ice-cold PBS and the cell suspension was
immediately centrifuged. The cell pellet was then lysed with NP-
40-digitonin lysis buffer (1% NP-40, 1% digitonin, 50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 10 mM EDTA, 2 mM sodium
vanadate and protease inhibitor cocktail [Calbiochem]). To
measure proliferation of PBMCs, Fc fusion proteins (2.5 mg) and
OKT3 (1 mg; purified from hybridoma supernatant) were
adsorbed onto Maxi-Sorb 96-well plates. 1610
5 PBMCs per well
were incubated in 200 ml of culture medium. PHA (Oxoid,
Basingstoke, UK) was added where indicated at 25 mg/ml. After
48 h, 0.4 mCi [
3H]-thymidine (Amersham Biosciences, Braunsch-
weig, Germany) was added. After 24 h the cells were harvested
and incorporated [
3H]-thymidine measured in a beta-counter
(Perkin Elmer, Rodgau, Germany).
Mass spectrometric analysis
Protein bands were excised manually from a preparative,
Coomassie-stained gel. After destaining two times with 100 mlo f
50% acetonitrile (ACN), 20 mM NH4HCO3 at 37uC for 30 min,
bands were dehydrated by adding 100 ml ACN and dried. 20 mlo f
sequencing grade trypsin (10 ng/ml; Promega) was added and
after 30 min incubation on ice remaining trypsin solution was
discarded. Digestion was continued at 37uC overnight and stopped
by adding 0.1% trifluoroacetic acid, 50% ACN. Tryptic peptides
were extracted with two times 20 ml 50% ACN, 0.1% formic acid
(FA) for 30 min at 37uC and 10 ml ACN for 30 min at RT. All
extracts were combined and dried in a vacuum centrifuge.
For LC-iontrap-MS analysis peptide samples were dissolved in
10 ml 10% ACN. Five microliter per peptide sample were injected
onto a C18 RP-Column (Zorbax SB, C18, 80 A ˚,5 mm,
15060,5 mm: Agilent) using a 1100 Series Agilent HPLC System
equipped with an autosampler, coupled online to an Esquire3000
+
ion trap mass spectrometer (Bruker Daltonics). Using a two buffer
system (A: 5% ACN, 0,1% FA; B: 80% ACN, 0,1% FA) and a flow
rate of 5 ml/min, a multi-step gradient was applied after injection:
0–5 min: 0% B; 30 min gradient to 53.9% B (40% ACN); 5 min
gradient to 100% B; increase of flow rate to 10 ml/min in 1 min;
10 min at 100% B; 4 min gradient to 0% B; 15 min at 0% B. The
MS method used to select and fragment the eluting peptides was
set to trigger fragmentation of the three most intensive peaks from
an MS scan at a 40,000 ion count threshold and a preference of
doubly charged ions. Automated precursor exclusion after one
acquired spectrum per precursor for 0.3 min was used. The ESI
source conditions were set to 10 psi nebulizer gas pressure with dry
gas heated to 300uC at a flow rate of 4.0 l/min. Mass spectro-
metrical data were searched against the SwissProt Database with
carbamidomethylation of cysteins as static and oxidation of
methionines as variable modification. For ion trap-MS 150 ppm
mass deviation was tolerated for precursors and 0.7 Da for peptide
fragments in MS/MS. At least two peptides with a Mascot peptide
ion score higher than 25 each were used as a threshold for protein
identification.
Supporting Information
Figure S1 Specificity of the rabbit antiserum raised
against the predicted extracellular domain of pUL11.
Immunoblot with the rabbit antiserum raised against the fusion
protein consisting of the predicted extracellular domain of pUL11
and the human IgG Fc domain (c.f. Figure S2). The rabbit serum
was pre-absorbed to rAdV GFP transduced cells to reduce non-
specific interactions. Lysates of A549 cells transduced with rAdV
UL11 (UL11), rAdV GFP (GFP), or left uninfected (U) were used to
prepare immunoblots and proteins were detected using pUL11 anti-
serum or for comparison using an antibody specific for the V5
epitope. Bands corresponding to the major 50 kDa form (arrow) and
to high molecular weight forms of pUL11 (bracket) are indicated.
(TIF)
Figure S2 Generation of the pUL11 and pUL6 Fc fusion
proteins. (A) Cartoons of the domains of the Fc fusion proteins.
(B, C) The UL11Fc and UL6Fc proteins harvested from the
supernatants of transduced or transfected 293T cells and purified
using protein A sepharose were separated by SDS-PAGE and
detected by Coomassie blue staining or by immunoblotting using
HRP conjugated anti-human IgG. (D) The UL11Fc or the control
Fc protein were treated with PNGase F and detected after
immunoblotting as in (C).
(TIF)
Figure S3 Blocking effects of CD45 antibodies on the
interaction of pUL11 with Jurkat cells. Jurkat cells were left
untreated (top panel) or incubated with 10 mg of the indicated
CD45 antibodies for 30 min, prior to incubation with UL11Fc
(black lines) or the Fc control protein (grey lines).
(TIF)
Acknowledgments
We thank David Rothstein, Gavin Wilkinson, Burkhart Schraven, Chris
Benedict, Jens Bohne, Nick Holmes, Gabriele Hahn, Andrew Davison,
Benno Woelk, Corinna Benkartek, Melanie Brinkmann, Hans-Gerhard
Burgert, and Peter Beverley for reagents and helpful advice, and the Laser
Microscopy Facility at Hannover Medical School, particularly Rudolf
Bauerfeind, for support.
Author Contributions
Conceived and designed the experiments: IG AP RS RJ MM PCKF.
Performed the experiments: IG LS CP AP RJ PCKF. Analyzed the data:
IG LS CP AP RJS RS TFS RJ MM PCKF. Contributed reagents/
materials/analysis tools: RJS. Wrote the paper: MM PCKF.
HCMV UL11 Inhibits CD45 Mediated T Cell Functions
PLoS Pathogens | www.plospathogens.org 13 December 2011 | Volume 7 | Issue 12 | e1002432References
1. Mocarski E, Shenk T, Pass R (2007) Cytomegaloviruses. In: Knipe DM,
Howley PM, eds. Fields’ Virology 5th Edition. Philadelphia (PA): Lippincott,
Williams and Wilkins. pp 2702–2772.
2. Jackson SE, Mason GM, Wills MR (2011) Human cytomegalovirus immunity
and immune evasion. Virus Res 157: 151–160.
3. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod’homme V, et al.
(2008) Modulation of natural killer cells by human cytomegalovirus. J Clin Virol
41: 206–212.
4. Go ¨rzer I, Kerschner H, Redlberger-Fritz M, Puchhammer-Sto ¨ckl E (2010)
Human cytomegalovirus (HCMV) genotype populations in immunocompetent
individuals during primary HCMV infection. J Clin Virol 48: 100–103.
5. Meyer-Ko ¨nig U, Ebert K, Schrage B, Pollak S, Hufert FT (1998) Simultaneous
infection of healthy people with multiple human cytomegalovirus strains. Lancet
352: 1280–1281.
6. Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, et al. (2010) Cytomegalovirus
reinfections in healthy seroimmune women. J Infect Dis 201: 386–389.
7. Powers C, DeFilippis V, Malouli D, Fru ¨h K (2008) Cytomegalovirus immune
evasion. Curr Top Microbiol Immunol 325: 333–359.
8. Britt W (2008) Manifestations of human cytomegalovirus infection: proposed
mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 325:
417–470.
9. Carney WP, Hirsch MS (1981) Mechanisms of immunosuppression in
cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis
144: 47–54.
10. Carney WP, Rubin RH, Hoffman RA, Hansen WP, Healey K, et al. (1981)
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol
126: 2114–2116.
11. Giebel S, Maccario R, Lilleri D, Zecca M, Avanzini MA, et al. (2005) The
immunosuppressive effect of human cytomegalovirus infection in recipients of
allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 36:
503–509.
12. Rinaldo CR, Jr., Carney WP, Richter BS, Black PH, Hirsch MS (1980)
Mechanisms of immunosuppression in cytomegaloviral mononucleosis. J Infect
Dis 141: 488–495.
13. Tu W, Chen S, Sharp M, Dekker C, Manganello AM, et al. (2004) Persistent
and selective deficiency of CD4+ T cell immunity to cytomegalovirus in
immunocompetent young children. J Immunol 172: 3260–3267.
14. Hirsch MS, Felsenstein D (1984) Cytomegalovirus-induced immunosuppression.
Ann N Y Acad Sci 437: 8–15.
15. Sia IG, Patel R (2000) New strategies for prevention and therapy of
cytomegalovirus infection and disease in solid-organ transplant recipients. Clin
Microbiol Rev 13: 83–121. table.
16. Basta S, Bennink JR (2003) A survival game of hide and seek: cytomegaloviruses
and MHC class I antigen presentation pathways. Viral Immunol 16: 231–242.
17. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S (2000)
Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10).
Proc Natl Acad Sci U S A 97: 1695–1700.
18. Michelson S, Alcami J, Kim SJ, Danielpour D, Bachelerie F, et al. (1994)
Human cytomegalovirus infection induces transcription and secretion of
transforming growth factor beta 1. J Virol 68: 5730–5737.
19. Senechal B, Boruchov AM, Reagan JL, Hart DN, Young JW (2004) Infection of
mature monocyte-derived dendritic cells with human cytomegalovirus inhibits
stimulation of T-cell proliferation via the release of soluble CD83. Blood 103:
4207–4215.
20. Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, et al. (2002) Potent
immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol
76: 1285–1292.
21. Raftery MJ, Schwab M, Eibert SM, Samstag Y, Walczak H, et al. (2001)
Targeting the function of mature dendritic cells by human cytomegalovirus: a
multilayered viral defense strategy. Immunity 15: 997–1009.
22. Barclay AN (2003) Membrane proteins with immunoglobulin-like domains - a
master superfamily of interaction molecules. Semin Immunol 15: 215–223.
23. Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL (2001) Virus
subversion of immunity: a structural perspective. Curr Opin Immunol 13:
442–450.
24. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, et al. (2002) Recognition
of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl
Acad Sci U S A 99: 8826–8831.
25. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, et al. (2004)
Genetic content of wild-type human cytomegalovirus. J Gen Virol 85:
1301–1312.
26. Davison AJ, Akter P, Cunningham C, Dolan A, Addison C, et al. (2003)
Homology between the human cytomegalovirus RL11 gene family and human
adenovirus E3 genes. J Gen Virol 84: 657–663.
27. Atalay R, Zimmermann A, Wagner M, Borst E, Benz C, et al. (2002)
Identification and expression of human cytomegalovirus transcription units
coding for two distinct Fcgamma receptor homologs. J Virol 76: 8596–8608.
28. Lilley BN, Ploegh HL, Tirabassi RS (2001) Human cytomegalovirus open
reading frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding
protein. J Virol 75: 11218–11221.
29. Hitomi S, Kozuka-Hata H, Chen Z, Sugano S, Yamaguchi N, et al. (1997)
Human cytomegalovirus open reading frame UL11 encodes a highly
polymorphic protein expressed on the infected cell surface. Arch Virol 142:
1407–1427.
30. Timon M, Arnaiz-Villena A, Ruiz-Contreras J, Ramos-Amador JT, Pacheco A,
et al. (1993) Selective impairment of T lymphocyte activation through the T cell
receptor/CD3 complex after cytomegalovirus infection. Clin Exp Immunol 94:
38–42.
31. Cale CM, Klein NJ, Novelli V, Veys P, Jones AM, et al. (1997) Severe combined
immunodeficiency with abnormalities in expression of the common leucocyte
antigen, CD45. Arch Dis Child 76: 163–164.
32. Kung C, Pingel JT, Heikinheimo M, Klemola T, Varkila K, et al. (2000)
Mutations in the tyrosine phosphatase CD45 gene in a child with severe
combined immunodeficiency disease. Nat Med 6: 343–345.
33. Tchilian EZ, Wallace DL, Wells RS, Flower DR, Morgan G, et al. (2001) A
deletion in the gene encoding the CD45 antigen in a patient with SCID.
J Immunol 166: 1308–1313.
34. Byth KF, Conroy LA, Howlett S, Smith AJ, May J, et al. (1996) CD45-null
transgenic mice reveal a positive regulatory role for CD45 in early thymocyte
development, in the selection of CD4+CD8+ thymocytes, and B cell maturation.
J Exp Med 183: 1707–1718.
35. Kishihara K, Penninger J, Wallace VA, Ku ¨ndig TM, Kawai K, et al. (1993)
Normal B lymphocyte development but impaired T cell maturation in CD45-
exon6 protein tyrosine phosphatase-deficient mice. Cell 74: 143–156.
36. Mee PJ, Turner M, Basson MA, Costello PS, Zamoyska R, et al. (1999) Greatly
reduced efficiency of both positive and negative selection of thymocytes in CD45
tyrosine phosphatase-deficient mice. Eur J Immunol 29: 2923–2933.
37. Stone JD, Conroy LA, Byth KF, Hederer RA, Howlett S, et al. (1997) Aberrant
TCR-mediated signaling in CD45-null thymocytes involves dysfunctional
regulation of Lck, Fyn, TCR-zeta, and ZAP-70. J Immunol 158: 5773–5782.
38. Barber EK, Dasgupta JD, Schlossman SF, Trevillyan JM, Rudd CE (1989) The
CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that
phosphorylates the CD3 complex. Proc Natl Acad Sci U S A 86: 3277–3281.
39. van Oers NS, Killeen N, Weiss A (1996) Lck regulates the tyrosine
phosphorylation of the T cell receptor subunits and ZAP-70 in murine
thymocytes. J Exp Med 183: 1053–1062.
40. Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R (2009) T-cell receptor
proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell
activation, differentiation, and tolerance. Immunol Rev 228: 9–22.
41. Amrein KE, Sefton BM (1988) Mutation of a site of tyrosine phosphorylation in
the lymphocyte-specific tyrosine protein kinase, p56lck, reveals its oncogenic
potential in fibroblasts. Proc Natl Acad Sci U S A 85: 4247–4251.
42. Eck MJ, Atwell SK, Shoelson SE, Harrison SC (1994) Structure of the regulatory
domains of the Src-family tyrosine kinase Lck. Nature 368: 764–769.
43. Marth JD, Cooper JA, King CS, Ziegler SF, Tinker DA, et al. (1988) Neoplastic
transformation induced by an activated lymphocyte-specific protein tyrosine
kinase (pp56lck). Mol Cell Biol 8: 540–550.
44. Ostergaard HL, Shackelford DA, Hurley TR, Johnson P, Hyman R, et al. (1989)
Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein
kinase in murine lymphoma T-cell lines. Proc Natl Acad Sci U S A 86:
8959–8963.
45. Xu H, Littman DR (1995) The kinase-dependent function of Lck in T-cell
activation requires an intact site for tyrosine autophosphorylation. Ann N Y Acad
Sci 766: 99–116.
46. Yamaguchi H, Hendrickson WA (1996) Structural basis for activation of human
lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384: 484–489.
47. Baker M, Gamble J, Tooze R, Higgins D, Yang FT, et al. (2000) Development
of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice.
EMBO J 19: 4644–4654.
48. D’Oro U, Sakaguchi K, Appella E, Ashwell JD (1996) Mutational analysis of Lck
in CD45-negative T cells: dominant role of tyrosine 394 phosphorylation in
kinase activity. Mol Cell Biol 16: 4996–5003.
49. McNeill L, Salmond RJ, Cooper JC, Carret CK, Cassady-Cain RL, et al. (2007)
The differential regulation of Lck kinase phosphorylation sites by CD45 is
critical for T cell receptor signaling responses. Immunity 27: 425–437.
50. Hermiston ML, Xu Z, Weiss A (2003) CD45: a critical regulator of signaling
thresholds in immune cells. Annu Rev Immunol 21: 107–137.
51. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW (2008)
Re-engineering adenovirus vector systems to enable high-throughput analyses of
gene function. Biotechniques 45: 659–8.
52. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, et al. (2008) Cloning and
sequencing of a highly productive, endotheliotropic virus strain derived from
human cytomegalovirus TB40/E. J Gen Virol 89: 359–368.
53. Irles C, Symons A, Michel F, Bakker TR, van der Merwe PA, et al. (2003) CD45
ectodomain controls interaction with GEMs and Lck activity for optimal TCR
signaling. Nat Immunol 4: 189–197.
54. van Vliet SJ, Gringhuis SI, Geijtenbeek TB, van Kooyk Y (2006) Regulation of
effector T cells by antigen-presenting cells via interaction of the C-type lectin
MGL with CD45. Nat Immunol 7: 1200–1208.
55. Thomas ML (1989) The leukocyte common antigen family. Annu Rev Immunol
7: 339–369.
56. McKenney DW, Onodera H, Gorman L, Mimura T, Rothstein DM (1995)
Distinct isoforms of the CD45 protein-tyrosine phosphatase differentially
HCMV UL11 Inhibits CD45 Mediated T Cell Functions
PLoS Pathogens | www.plospathogens.org 14 December 2011 | Volume 7 | Issue 12 | e1002432regulate interleukin 2 secretion and activation signal pathways involving Vav in
T cells. J Biol Chem 270: 24949–24954.
57. Koretzky GA, Picus J, Thomas ML, Weiss A (1990) Tyrosine phosphatase CD45
is essential for coupling T-cell antigen receptor to the phosphatidyl inositol
pathway. Nature 346: 66–68.
58. Schwinzer R, Schraven B, Kyas U, Meuer SC, Wonigeit K (1992) Phenotypical
and biochemical characterization of a variant CD45R expression pattern in
human leukocytes. Eur J Immunol 22: 1095–1098.
59. Terry LA, Brown MH, Beverley PC (1988) The monoclonal antibody, UCHL1,
recognizes a 180,000 MW component of the human leucocyte-common antigen,
CD45. Immunology 64: 331–336.
60. Earl LA, Baum LG (2008) CD45 glycosylation controls T-cell life and death.
Immunol Cell Biol 86: 608–615.
61. Young JL, Ramage JM, Gaston JS, Beverley PC (1997) In vitro responses of
human CD45R0brightRA- and CD45R0-RAbright T cell subsets and their
relationship to memory and naive T cells. Eur J Immunol 27: 2383–2390.
62. Thude H, Hundrieser J, Wonigeit K, Schwinzer R (1995) A point mutation in
the human CD45 gene associated with defective splicing of exon A. Eur J
Immunol 25: 2101–2106.
63. Zilch CF, Walker AM, Timon M, Goff LK, Wallace DL, et al. (1998) A point
mutation within CD45 exon A is the cause of variant CD45RA splicing in
humans. Eur J Immunol 28: 22–29.
64. Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation. Annu Rev
Immunol 27: 591–619.
65. Razonable RR (2005) Epidemiology of cytomegalovirus disease in solid organ
and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 62:
S7–13.
66. Windheim M, Burgert HG (2002) Characterization of E3/49K, a novel, highly
glycosylated E3 protein of the epidemic keratoconjunctivitis-causing adenovirus
type 19a. J Virol 76: 755–766.
67. Antonsson A, Johansson PJ (2001) Binding of human and animal immunoglob-
ulins to the IgG Fc receptor induced by human cytomegalovirus. J Gen Virol 82:
1137–1145.
68. MacCormac LP, Grundy JE (1996) Human cytomegalovirus induces an Fc
gamma receptor (Fc gammaR) in endothelial cells and fibroblasts that is distinct
from the human cellular Fc gammaRs. J Infect Dis 174: 1151–1161.
69. Varki A, Crocker PR (2009) I-type Lectins. In: Varki A, Cummings RD,
Esko JD, Freeze HH, Stanley P, et al. (2009) Essentials of Glycobiology. Cold
Spring Harbor (NY): Cold Spring Harbor Laboratory Press. pp 459–474.
70. Baldwin TA, Ostergaard HL (2001) Developmentally regulated changes in
glucosidase II association with, and carbohydrate content of, the protein tyrosine
phosphatase CD45. J Immunol 167: 3829–3835.
71. Uemura K, Yokota Y, Kozutsumi Y, Kawasaki T (1996) A unique CD45
glycoform recognized by the serum mannan-binding protein in immature
thymocytes. J Biol Chem 271: 4581–4584.
72. Rachmilewitz J, Borovsky Z, Riely GJ, Miller R, Tykocinski ML (2003) Negative
regulation of T cell activation by placental protein 14 is mediated by the tyrosine
phosphatase receptor CD45. J Biol Chem 278: 14059–14065.
73. Straus DB, Weiss A (1992) Genetic evidence for the involvement of the lck
tyrosine kinase in signal transduction through the T cell antigen receptor. Cell
70: 585–593.
74. Hermiston ML, Xu Z, Majeti R, Weiss A (2002) Reciprocal regulation of
lymphocyte activation by tyrosine kinases and phosphatases. J Clin Invest 109:
9–14.
75. Ilangumaran S, Arni S, Echten-Deckert G, Borisch B, Hoessli DC (1999)
Microdomain-dependent regulation of Lck and Fyn protein-tyrosine kinases in T
lymphocyte plasma membranes. Mol Biol Cell 10: 891–905.
76. Harder T, Engelhardt KR (2004) Membrane domains in lymphocytes - from
lipid rafts to protein scaffolds. Traffic 5: 265–275.
77. Furukawa T, Itoh M, Krueger NX, Streuli M, Saito H (1994) Specific
interaction of the CD45 protein-tyrosine phosphatase with tyrosine-phosphor-
ylated CD3 zeta chain. Proc Natl Acad Sci U S A 91: 10928–10932.
78. Mustelin T, Williams S, Tailor P, Couture C, Zenner G, et al. (1995) Regulation
of the p70zap tyrosine protein kinase in T cells by the CD45 phosphotyrosine
phosphatase. Eur J Immunol 25: 942–946.
79. Freiberg BA, Kupfer H, Maslanik W, Delli J, Kappler J, et al. (2002) Staging and
resetting T cell activation in SMACs. Nat Immunol 3: 911–917.
80. Parikh K, Poppema S, Peppelenbosch MP, Visser L (2009) Extracellular
ligation-dependent CD45RB enzymatic activity negatively regulates lipid raft
signal transduction. Blood 113: 594–603.
81. Ish-Shalom E, Gargir A, Andre S, Borovsky Z, Ochanuna Z, et al. (2006)
alpha2,6-Sialylation promotes binding of placental protein 14 via its Ca2+-
dependent lectin activity: insights into differential effects on CD45RO and
CD45RA T cells. Glycobiology 16: 173–183.
82. Bilwes AM, den Hertog J, Hunter T, Noel JP (1996) Structural basis for
inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization.
Nature 382: 555–559.
83. Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, et al. (2000) An inactivating
point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and
autoimmunity. Cell 103: 1059–1070.
84. Do HT, Baars W, Borns K, Windhagen A, Schwinzer R (2006) The 77C-.G
mutation in the human CD45 (PTPRC) gene leads to increased intensity of
TCR signaling in T cell lines from healthy individuals and patients with multiple
sclerosis. J Immunol 176: 931–938.
85. Windhagen A, Sonmez D, Hornig-Do HT, Kalinowsky A, Schwinzer R (2007)
Altered CD45 isoform expression in C77G carriers influences cytokine
responsiveness and adhesion properties of T cells. Clin Exp Immunol 150:
509–517.
86. Amano M, Galvan M, He J, Baum LG (2003) The ST6Gal I sialyltransferase
selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced
CD45 clustering, phosphatase modulation, and T cell death. J Biol Chem 278:
7469–7475.
87. Desai DM, Sap J, Schlessinger J, Weiss A (1993) Ligand-mediated negative
regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell 73:
541–554.
88. Borst EM, Benkartek C, Messerle M (2007) Use of bacterial artificial
chromosomes in generating targeted mutations in human and mouse
cytomegaloviruses. Curr Protoc Immunol, Chapter 10: 32.1–32.20.
89. Cheung TC, Humphreys IR, Potter KG, Norris PS, Shumway HM, et al. (2005)
Evolutionarily divergent herpesviruses modulate T cell activation by targeting
the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci U S A
102: 13218–13223.
90. Borst EM, Hahn G, Koszinowski UH, Messerle M (1999) Cloning of the human
cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromo-
some in Escherichia coli: a new approach for construction of HCMV mutants.
J Virol 73: 8320–8329.
91. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, et al. (1996) Human
cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory
strains. J Virol 70: 78–83.
92. Hildinger M, Abel KL, Ostertag W, Baum C (1999) Design of 59 untranslated
sequences in retroviral vectors developed for medical use. J Virol 73: 4083–4089.
93. Schambach A, Mueller D, Galla M, Verstegen MM, Wagemaker G, et al. (2006)
Overcoming promoter competition in packaging cells improves production of
self-inactivating retroviral vectors. Gene Ther 13: 1524–1533.
94. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK (1995) High-titer
packaging cells producing recombinant retroviruses resistant to human serum.
J Virol 69: 7430–7436.
95. Ogilvy S, Louis-Dit-Sully C, Cooper J, Cassady RL, Alexander DR, et al. (2003)
Either of the CD45RB and CD45RO isoforms are effective in restoring T cell,
but not B cell, development and function in CD45-null mice. J Immunol 171:
1792–1800.
96. Weiss A, Stobo JD (1984) Requirement for the coexpression of T3 and the T cell
antigen receptor on a malignant human T cell line. J Exp Med 160: 1284–1299.
HCMV UL11 Inhibits CD45 Mediated T Cell Functions
PLoS Pathogens | www.plospathogens.org 15 December 2011 | Volume 7 | Issue 12 | e1002432